Shamseddine A.; Farhat F.S.; Elias E.; Khauli R.B.; Saleh A.; Bulbul M.A.
(BASELALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND, 2013)
Introduction: Docetaxel has become the standard chemotherapy for patients with castration-resistant prostate cancer (CRPC). We wanted to assess the efficacy and safety of a weekly high-dose calcitriol, docetaxel and ...